BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors

Cancer Discovery

Volumn 2, Issue 9, 2012, Pages 791-797

  Dahlman, Kimberly Brown ^a,b   Xia, Junfeng ^b   Hutchinson, Katherine ^b   Ng, Charles ^d   Hucks, Donald ^a   Jia, Peilin ^b   Atefi, Mohammad ^d   Su, Zengliu ^a   Branch, Suzanne ^d   Lyle, Pamela L ^c   Hicks, Donna J ^a   Bozon, Viviana ^g   Glaspy, John A ^d,e   Rosen, Neal ^f   Solit, David B ^f   Netterville, James L ^a,b   Vnencak Jones, Cindy L ^b,c   Sosman, Jeffrey A ^a,b   Ribas, Antoni ^d,e   Zhao, Zhongming ^a,b   Pao, William ^a,b   more..

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Division of Hematology Oncology   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; LEUCINE; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TAK 733; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

AGED; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MUTATION RATE; MUTATIONAL ANALYSIS; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING;

AGED; CELL LINE, TUMOR; GENOME, HUMAN; HUMANS; MALE; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES;

EID: 84866342282     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0097     Document Type: Article

References (25)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
3. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, openlabel, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904-9.
4. Lovly CM, Dahlman KB, Fohn L, Su Z, Dias-Santagata D, Hicks DJ, et al. Routine mutational profiling of melanomas enables enrollment in genotype-driven trials. PLoS One 2012;7:e35309.
5. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-50.
6. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-21.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
8. Dong Q, Dougan DR, Gong X, Halkowycz P, Jin B, Kanouni T, et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg Med Chem Lett 2011; 21: 1315-9.
9. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-14.
10. Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn 2011; 13: 504-13.
11. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010; 70: 5518-27.
12. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol, 28: 15s, 2010 (suppl; abstr 8503).
13. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-901.
14. Kim KB, Kefford R, Pavlick A, Infante JR, Ribas A, Sosman J A, et al. A Phase II study of the MEK1/MEK2 inhibitor GSK1120212 in metastatic BRAF-mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor [abstract]. In: Proceedings of the 8th International Congress of The Society for Melanoma Research; 2011 Nov 9-13; Tampa, FL. p. 990-1075.
15. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011; 43: 442-6.
16. Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 2007; 44: 131-5.
17. Sovik O, Schubbert S, Houge G, Steine SJ, Norgard G, Engelsen B, et al. De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet 2007; 44: e84.
18. Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006; 38: 331-6.
19. Quilliam LA, Zhong S, Rabun KM, Carpenter JW, South TL, Der CJ, et al. Biological and structural characterization of a Ras transforming mutation at the phenylalanine-156 residue, which is conserved in all members of the Ras superfamily. Proc Natl Acad Sci U S A 1995; 92: 1272-6.
20. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347-51.
21. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008; 456: 53-9.
22. FastQC A quality control tool for high throughput sequence data. version 0.9.1. [Internet]. [cited 2012 Mar 5]. Available from: http:// www.bioinformatics.bbsrc.ac.uk/projects/fastqc/.
23. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wildtype BRAF. Nature 2010; 464: 427-30.
24. Sosman J. First-in-human, multicenter, dose-escalation, phase I study of the investigatioal drug TAK-733, an oral MEK inhibitor, in patients with advanced nonhematologic malignancies and melanoma. J Clin Oncol 29: 2011 (suppl; abstr TPS145).
25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.